|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 在直肠的癌症的磁性的回声成像调查结果的临床的意义显示文摘 Staging of rectal cancer is essential to help guide clini-cians to decide upon the correct type of surgery and determine whether or not neoadjuvant therapy is indicated. Magnetic resonance imaging (MRI) is currently one of the most accurate modalities on which to base treatment decisions for patients with rectal cancer. MRI can accurately detect the mesorectal fascia, assess the invasion of the mesorectum or surrounding organs and predict the circumferential resection margin. Although nodal disease remains a difficult radiological diagnosis, new lymphographic agents and diffusion weighted imaging may allow identification of metastatic nodes by criteria other then size. In light of this, we have reviewed the literature on the accuracy of specific MRI findings for staging the local extent of primary rectal cancer. The aim of this review is to establish a correlation between MRI findings, prognosis, and available treatment options. | Charles F Bellows Bernard Jaffe Lorenzo Bacigalupo Salvatore Pucciarelli Guiseppe Gagliardi | 2011 | World Journal of Radiology2011，3，4： | 19 |
| 2 | Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression显示文摘Gastrointestinal cancer is a group of tumors that affect multiple sites of the digestive system, including the stomach, liver, colon and pancreas. These cancers are very aggressive and rapidly metastasize, thus identifying effective targets is crucial for treatment. Galectin-1(Gal-1) belongs to a family of glycan-binding proteins, or lectins, with the ability to cross-link specific glycoconjugates. A variety of biological activities have been attributed to Gal-1 at different steps of tumor progression. Herein, we summarize the current literature regarding the roles of Gal-1 in gastrointestinal malignancies. Accumulating evidence shows that Gal-1 is drastically up-regulated in human gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic ductal adenocarcinoma tissues, both in tumor epithelial and tumor-associated stromal cells. Moreover, Gal-1 makes a crucial contribution to the pathogenesis of gastrointestinal malignancies, favoring tumor development, aggressiveness, metastasis, immunosuppression and angiogenesis. We also highlight that alterations in Gal-1-specific glycoepitopes may be relevant for gastrointestinal cancer progression. Despite the findings obtained so far, further functional studies are still required. Elucidating the precise molecular mechanisms modulated by Gal-1 underlying gastrointestinal tumor progression, might lead to the development of novel Gal-1-based diagnostic methods and/or therapies. | maría l bacigalupo pablo carabias maría f troncoso | 2017 | World Journal of Gastroenterology2017，23，29： | 11 |
| 3 | MicroRNAs contribute to ATP-binding cassette transporter-and autophagy-mediated chemoresistance in hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) has an elevated mortality rate, largely because of high recurrence and metastasis. Additionally, the main obstacle during treatment of HCC is that patients usually develop resistance to chemotherapy.Cancer drug resistance involves many different mechanisms, including alterations in drug metabolism and processing, impairment of the apoptotic machine, activation of cell survival signaling, decreased drug sensitivity and autophagy, among others. Nowadays, miRNAs are emerging as master regulators of normal physiology-and tumor-related gene expression. In HCC,aberrant expression of many miRNAs leads to chemoresistance. Herein, we particularly analyzed miRNA impact on HCC resistance to drug therapy. Certain miRNAs target ABC(ATP-binding cassette) transporter genes. As most of these miRNAs are downregulated in HCC, transporter levels increase and intracellular drug accumulation decrease, turning cells less sensitive to death. Others miRNAs target autophagy-related gene expression, inhibiting autophagy and acting as tumor suppressors. Nevertheless, due to its downregulation in HCC, these miRNAs do not inhibit autophagy or tumor growth and, resistance is favored.Concluding, modulation of ABC transporter and/or autophagy-related gene expression or function by miRNAs could be determinant for HCC cell survival under chemotherapeutic drug treatment. Undoubtedly, more insights on the biological processes, signaling pathways and/or molecular mechanisms regulated by miRNAs are needed. Anyway, miRNA-based therapy together with conventional chemotherapeutic drugs has a great future in cancer therapy. | María V Espelt María L Bacigalupo Pablo Carabias María F Troncoso | 2019 | World Journal of Hepatology2019，11，4： | 3 |
| 4 | Aplastic Anemia: Pathophysiology and Treatment显示文摘 | Neal S. Young Andrea Bacigalupo Judith C.W. Marsh | 2010 | Biology of Blood and Marrow Transplantation2010，，1： | 3 |
| 5 | Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC)represents a global health problem.Infections with hepatitis B or C virus,non-alcoholic steatohepatitis disease,alcohol abuse,or dietary exposure to aflatoxin are the major risk factors to the development of this tumor.Regardless of the carcinogenic insult,HCC usually develops in a context of cirrhosis due to chronic inflammation and advanced fibrosis.Galectins are a family of evolutionarily-conserved proteins defined by at least one carbohydrate recognition domain with affinity forβ-galactosides and conserved sequence motifs.Here,we summarize the current literature implicating galectins in the pathogenesis of HCC.Expression of'proto-type'galectin-1,'chimera-type'galectin-3 and'tandem repeat-type'galectin-4 is up-regulated in HCC cells compared to their normal counterparts.On the other hand,the'tandemrepeat-type'lectins galectin-8 and galectin-9 are downregulated in tumor hepatocytes.The abnormal expression of these galectins correlates with tumor growth,HCC cell migration and invasion,tumor aggressiveness,metastasis,postoperative recurrence and poor prognosis.Moreover,these galectins have important roles in other pathological conditions of the liver,where chronic inflammation and/or fibrosis take place.Galectin-based therapies have been proposed to attenuate liver pathologies.Further functional studies are required to delineate the precise molecular mechanisms through which galectins contribute to HCC. | María L Bacigalupo Malena Manzi Gabriel A Rabinovich María F Troncoso | 2013 | World Journal of Gastroenterology2013，19，47： | 2 |
| 6 | Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity显示文摘AIM: To investigate the toxicity and response of intensity-modulated radiotherapy schedule intensified with a simultaneous integrated boost in anal canal cancer.METHODS: From March 2009 to March 2014, we retrospectively analyzed 41 consecutive patients treated with intensity-modulated radiotherapy(IMRT) and concurrent chemotherapy for anal canal squamous cell carcinoma at our center. Radiotherapy was delivered via simultaneous integrated boost(SIB) technique by helical tomotherapy, and doses were adapted to two clinical target volumes according to the tumor-nodemetastasis(TNM) stage: 50.6 Gy and 41.4 Gy in 23 fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractionsin T2N0, and 55 Gy and 45 Gy in 25 fractions in all patients with N positive and/or ≥ T3, respectively, to planning target volumes 1 and 2. The most common chemotherapy regimen was 5-fluorouracil and mitomycin-based. Human papilloma virus(HPV) p16 expression was performed by immunohistochemistry and evaluated in the majority of patients. Acute and late toxicity was scored according to CTCAe v 3.0 and RTOG scales.RESULTS: The median follow-up was 30 mo(range:12-71). Median age was 63 years(range 32-84). The stage of disease was: stage Ⅰ in 2 patients, stage Ⅱin 13 patients, stage ⅢA in 12 patients, and stage ⅢB in 14 patients, respectively. Two patients were known to be HIV positive(4.9%). HPV p16 expression status was positive in 29/34(85.3%) patients. The 4-year progression-free survival and overall survival in HPVpositive patients were 78% and 92%, respectively.Acute grade 3 skin and gastrointestinal toxicities were reported in 5% and 7.3% of patients, respectively;patients' compliance to the treatment was good due to a low occurrence of severe acute toxicity, although treatment interruptions due to toxicity were required in 7.3% of patients. At 6 mo from end of treatment,36/40(90%) patients obtained complete response;during follow-up, 5(13.8%) patients presented with disease progression(local or systemic).CONCLUSION: In our experience, intensified SIBIMRT with chemotherapy is very feasible in clinical practice, with excellent results in terms of overall survival and local control. | Liliana Belgioia Stefano Vagge Dario Agnese Stefania Garelli Roberto Murialdo Giuseppe Fornarini Silvana Chiara Fabio Gallo Almalina Bacigalupo Renzo Corvò | 2015 | World Journal of Gastroenterology2015，21，37： | 2 |
| 7 | The type of graft versus host disease prophylaxis influences the degree of hematopoietic chimerism following allogeneic bone marrow transplantation for severe aplastic anemia-a comparison between cyclosporine and cyclosporine and Methotrexate显示文摘 | McCann SR Passweg JR Bacigalupo A | 2003 | Bone Marrow Transplant2003，31，1： | 1 |
| 8 | Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients显示文摘 | Viale M Merli A Bacigalupo A | 1991 | Blood1991，78，： | 1 |
| 9 | Comparison of time- resolved fluoroimmunoassay and immunoenzymometric assay for clenbnterol 显示文摘 | Bacigalupo MA Ius A Meroni G | 1995 | Analyst1995，120，： | 1 |
| 10 | Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia u- sing {ludarabine-based conditioning: a comparison with conventional conditioning regimen显示文摘 | MAURY S BACIGALUPO A ANDERLINI P | 2009 | Haemato- logica2009，94，： | 1 |
| 11 | Bone marrow trans- plantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party显示文摘 | Bacigalupo A Hows J Gluckman E | 1988 | Br J Haematol1988，70，2： | 1 |
| 12 | Diagnosis and treatment of acquired aplastic anemia显示文摘 | BACIGALUPO A PASSWEG J | 2009 | Hematol Oncol Clin North Am2009，23，： | 1 |
| 13 | CT of the abdomen : degree and quality of enhancement obtained with two concentrations of the same iodinated contrast medium with fixed iodine delivery rate and total iodine load 显示文摘 | Paparo F Garello I Bacigalupo L | 2014 | Eur J Radio12014，83，11： | 1 |
| 14 | Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with therapy-The European Group for Blood and Marrow transplantation experience 显示文摘 | Bacigalupo A Brand R Oneto R | 2000 | Semin Hernatol2000，37，8： | 1 |
| 15 | Defining the intensity of conditioning regimens : working definitions 显示文摘 | Bacigalupo A Ballen K Rizzo D | 2009 | Biol Blood Marrow Transplant2009，15，12： | 1 |
| 16 | Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation显示文摘 | Euler HH Marmont AM Bacigalupo A | 1996 | Blood1996，88，9： | 1 |
| 17 | Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methylpred nisolone (MPred) with or without androgens:a randomized trial from the EBMTSAA working party显示文摘 | Bacigalupo A Chaple M Hows J | 1993 | Br J Haematol1993，83，1： | 1 |
| 18 | Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Work- ing Party显示文摘 | Marsh JC Bacigalupo A Schrezenmeier H | 2012 | Blood2012，119，23： | 1 |
| 19 | Outcome of patients with acguired aplastic anemia given first line bone marrow trans-plantation or immunosuppressive treatment in the last decade:A report from the eurropean group for blood and marrow transplantion (EBMT)显示文摘 | Oneto R Bacigalupo A et aL Severe aplastic anemia work-ing party of the eurropean blood and marrow transplant group | 2007 | Haematologica2007，92，6： | 1 |
| 20 | Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulationg factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients: European Group for Blood and Marrow Transplantation(EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo(GITMO) 显示文摘 | Bacigalupo A Bruno B Saracco P | 2000 | Blood2000，95，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员